Clinical Trial

Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The main objective of this study is to evaluate the persistence of Japanese encephalitis antibodies in participants at the age of 6, after they have followed different Japanese encephalitis vaccination schedules. Furthermore, the study will assess the immunogenicity and antibody persistence of primary immunization across different Japanese encephalitis vaccination schedules, as well as the immunogenicity following booster immunizations within these schedules. The safety of each vaccine dose will also be evaluated.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-09; most recent amendment 2025-03-10.
Trial Details
NCT Number NCT06825312
Lead Sponsor Liaoning Chengda Biotechnology CO., LTD
Collaborators: Zhejiang Provincial Center for Disease Control and Prevention
Conditions Japanese Encephalitis Vaccine
Enrollment 600 participants
Start Date 2023-11-11
Primary Completion 2030-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-11